Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: Implications for surgical management and adjuvant therapies

Diseases of the Colon and Rectum

Volumn 49, Issue 5, 2006, Pages 609-615

  Hassan, Imran ^a   You, Y Nancy ^a   Dozois, Eric J ^a   Shayyan, Roman ^a   Smyrk, Thomas C ^a   Okuno, Scott H ^a   Donohue, John H ^a  

^a MAYO CLINIC   (United States)

Author keywords

Colon; Gastrointestinal stromal tumors; KIT; Rectum; Surgery

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; COLON RESECTION; COLON TUMOR; COLORECTAL SURGERY; COLORECTAL TUMOR; DISEASE COURSE; EVALUATION RESEARCH; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL EXCISION; MALE; METASTASIS; MITOSIS RATE; NATIONAL INSTITUTE OF HEALTH CRITERION; PATHOLOGY; RADICAL RECTUM RESECTION; RECTUM RESECTION; RECTUM TUMOR; REVIEW; RISK ASSESSMENT; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; COLONIC NEOPLASMS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECTAL NEOPLASMS; RISK ASSESSMENT;

EID: 33646543703     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/s10350-006-0503-8     Document Type: Review

References (34)

1. TS Emory LH Sobin L Lukes DH Lee TJ O'Leary 1999 Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site Am J Surg Pathol 23 82 87
2. RP Dematteo MC Heinrich WM El-Rifai G Demetri 2002 Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 466 477
3. S Hirota K Isozaki Y Moriyama 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580
4. MC Heinrich CD Blanke BJ Druker CL Corless 2002 Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies J Clin Oncol 20 1692 1703
5. GD Demetri M von Mehren CD Blanke 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480
6. AT van Oosterom IR Judson J Verweij 2002 Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 38 (Suppl 5) S83 S87
7. J Verweij PG Casali J Zalcberg 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127 1134
8. J Verweij A van Oosterom JY Blay 2003 Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study EurJ Cancer 39 2006 2011
9. BL Eisenberg I Judson 2004 Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy Ann Surg Oncol 11 465 475
10. M Miettinen M Furlong M Sarlomo-Rikala 2001 Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases Am J Surg Pathol 25 1121 1133
11. JA Tworek JR Goldblum SW Weiss JK Greenson HD Appelman 1999 Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases Am J Surg Pathol 23 937 945
12. M Miettinen LH Sobin J Lasota 2005 Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up Am J Surg Pathol 29 52 68
13. M Miettinen J Kopczynski HR Makhlouf 2003 Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases Am J Surg Pathol 27 625 641
14. RP DeMatteo JJ Lewis D Leung 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns andprognostic factors for survival Ann Surg 231 51 58
15. PC Wu A Langerman CW Ryan 2003 Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era Surgery 134 656 665
16. T Aparicio V Boige JC Sabourin 2004 Prognostic factorsafter surgery of primary resectable gastrointestinalstromal tumours Eur J Surg Oncol 30 1098 1103
17. I Besana-Ciani L Boni G Dionigi A Benevento R Dionigi 2003 Outcome and long term results of surgicalresection for gastrointestinal stromal tumors (GIST) Scandinavian Journal of Surgery: SJS 92 195 199
18. CR Antonescu A Viale L Sarran 2004 Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site Clin Cancer Res 10 3282 3290
19. B Wasag M Debiec-Rychter P Pauwels 2004 Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site Mod Pathol 17 889 894
20. M Miettinen LH Sobin M Sarlomo-Rikala 2000 Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT) Mod Pathol 13 1134 1142
21. JA Tworek JR Goldblum SW Weiss JK Greenson HD Appelman 1999 Stromal tumors of the anorectum: a clinicopathologic study of 22 cases Am J Surg Pathol 23 946 954
22. CR Changchien MC Wu WS Tasi 2004 Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining Dis Colon Rectum 47 1922 1929
23. CD Fletcher JJ Berman C Corless 2002 Diagnosis of gastrointestinal stromal tumors: A consensus approach Hum Pathol 33 459 465
24. W Ruka P Rutkowski Z Nowecki A Nasierowska-Guttmejer M Debiec-Rychter 2004 Other malignant neoplasms in patients with gastrointestinal stromal tumors (GIST) Med Sci Monit 10 LE13 LE14
25. M Chacon E Roca M Barugel 2004 Report of solid cancer in patients (pts) with gastrointestinal stromal tumours (GIST) Journal of Clinical Oncology ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 9065
26. M Miettinen M Sarlomo-Rikala LH Sobin 2001 Mesenchymal tumors of muscularis mucosae of colon and rectum are benign leiomyomas that should be separated from gastrointestinal stromal tumors-a clinicopathologic and immunohistochemical study of eighty-eight cases Mod Pathol 14 950 956
27. M Miettinen KM Shekitka LH Sobin 2001 Schwannomas in the colon and rectum: a clinicopathologic and immunohistochemical study of 20 cases Am J Surg Pathol 25 846 855
28. F Medeiros CL Corless A Duensing 2004 KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications Am J Surg Pathol 28 889 894
29. MC Heinrich CL Corless A Duensing 2003 PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 708 710
30. S Hirota A Ohashi T Nishida 2003 Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors Gastroenterology 125 660 667
31. CL Corless JA Fletcher MC Heinrich 2004 Biology of gastrointestinal stromal tumors J Clin Oncol 22 3813 3825
32. M Miettinen M Sarlomo-Rikala LH Sobin J Lasota 2000 Gastrointestinal stromal tumors and leiomyosarcomas in the colon: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases Am J Surg Pathol 24 1339 1352
33. I Hassan SZ Park JH Donohue 2004 Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience Ann Surg 239 244 250
34. Dematteo RP, Antonescu CR, Chadaram Y, et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S Intergroup Phase II trial ACOSOG Z9000 [abstract]. Proceedings of the American Society of Clinical Oncology 2005;22:9009.